Double-responsive hyaluronic acid-based prodrugs for efficient tumour targeting

IF 8.1 1区工程技术 Q1 MATERIALS SCIENCE, BIOMATERIALS

Materials science & engineering. C, Materials for biological applications Pub Date : 2021-12-01 DOI:10.1016/j.msec.2021.112475

Vincenzo Quagliariello , Arianna Gennari , Som Akshay Jain , Francesco Rosso , Rosario Vincenzo Iaffaioli , Alfonso Barbarisi , Manlio Barbarisi , Nicola Tirelli

{"title":"Double-responsive hyaluronic acid-based prodrugs for efficient tumour targeting","authors":"Vincenzo Quagliariello , Arianna Gennari , Som Akshay Jain , Francesco Rosso , Rosario Vincenzo Iaffaioli , Alfonso Barbarisi , Manlio Barbarisi , Nicola Tirelli","doi":"10.1016/j.msec.2021.112475","DOIUrl":null,"url":null,"abstract":"<div><p>Hyaluronic acid (HA)-based prodrugs bearing double-responsive (acid pH or oxidation) boronates of catechol-containing drugs were used to treat xenografted human prostate tumours (LNCaP) in SCID mice. The HA prodrugs accumulated significantly only in tumours (impressively, up to 40% of the injected dose after 24 h) and in liver, with negligible – actually anti-inflammatory - consequences in the latter. A quercetin-HA prodrug significantly slowed down tumour growth, in a dose-dependent fashion and with a much higher efficacy (up to 4 times) than equivalent doses of free quercetin. In short, boronated HA appears to be a very promising platform for targeted chemotherapy.</p></div>","PeriodicalId":18212,"journal":{"name":"Materials science & engineering. C, Materials for biological applications","volume":null,"pages":null},"PeriodicalIF":8.1000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0928493121006159/pdfft?md5=6c6310230d5c4577ead76049f7bd87b9&pid=1-s2.0-S0928493121006159-main.pdf","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Materials science & engineering. C, Materials for biological applications","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928493121006159","RegionNum":1,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 7

Abstract

Hyaluronic acid (HA)-based prodrugs bearing double-responsive (acid pH or oxidation) boronates of catechol-containing drugs were used to treat xenografted human prostate tumours (LNCaP) in SCID mice. The HA prodrugs accumulated significantly only in tumours (impressively, up to 40% of the injected dose after 24 h) and in liver, with negligible – actually anti-inflammatory - consequences in the latter. A quercetin-HA prodrug significantly slowed down tumour growth, in a dose-dependent fashion and with a much higher efficacy (up to 4 times) than equivalent doses of free quercetin. In short, boronated HA appears to be a very promising platform for targeted chemotherapy.

Abstract Image

查看原文本刊更多论文

基于透明质酸的双反应前药有效靶向肿瘤

以透明质酸(HA)为基础的前药含有儿茶酚类药物的双响应(酸性pH或氧化)硼酸盐，用于治疗SCID小鼠的异种移植人前列腺肿瘤(LNCaP)。透明质酸前药仅在肿瘤(令人印象深刻的是，24小时后高达注射剂量的40%)和肝脏中显著积累，后者的效果可以忽略不计——实际上是抗炎作用。槲皮素- ha前药以剂量依赖的方式显著减缓肿瘤生长，其功效远高于同等剂量的游离槲皮素(高达4倍)。简而言之，硼化透明质酸似乎是一个非常有前途的靶向化疗平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Materials science & engineering. C, Materials for biological applications MATERIALS SCIENCE, BIOMATERIALS-

CiteScore

12.60

自引率

0.00%

发文量

审稿时长

3.3 months

期刊介绍： Materials Today is a community committed to fostering the creation and sharing of knowledge and experience in materials science. With the support of Elsevier, this community publishes high-impact peer-reviewed journals, organizes academic conferences, and conducts educational webinars, among other initiatives. It serves as a hub for advancing materials science and facilitating collaboration within the scientific community.